… trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for progression
to … Molnupiravir is an orally administered antiviral Covid-19 treatment that currently has …

… Molnupiravir and nirmatrelvir plus ritonavir were granted an emergency … for treating outpatients
with first-ever SARS-CoV-2 infection confirmed by PCR (aged ≥18 years for molnupiravir …

… molnupiravir is currently only available under emergency use authorization for the treatment
of adults … Here, we explained why molnupiravir failed for the treatment of COVID-19 in …

… non-hospitalized adults with COVID-19. While no clinical benefits have been observed with
molnupiravir … early (i) molnupiravir or (ii) nirmatrelvir/ritonavir treatment at public hospitals …

… treatment for mild-to-moderate coronavirus disease 2019 (Covid-19). The efficacy of this
treatment in … safety of nirmatrelvir–ritonavir in nonhospitalized adults with symptomatic Covid-19 …

… of COVID-19 in nonhospitalized patients.  … Meaning In this study, viral rebound was
uncommon in adults with COVID-19 after treatment with nirmatrelvir-ritonavir and molnupiravir, …

… risk reduction of hospitalization or mortality in non-hospitalized patients infected with mild-to…
treatment with MOL reduced the risk of hospitalization or death in at-risk, unvaccinated adults …

… Molnupiravir initially emerged as a possible treatment of influenza viruses, encephalitic …
to assess efficacy and safety of molnupiravir in 1850 non-hospitalized adult (18 years or older) …

… of severe outcomes between Paxlovid users and those treated with molnupiravir [10] (a
third-line … We conducted a population-based cohort study with all adults (≥18 years old) within …

Introduction We compared the effectiveness and virological clearance (VC) at day 7 (T7)
post-treatment with molnupiravir, nirmatrelvir/ritonavir, and remdesivir in SARS-CoV-2-infected …